TYRX Absorbable Antibacterial Envelope

Helping Reduce Infections in Pacing Systems and CIEDs


The TYRX™ Absorbable Antibacterial Envelope is the only fully absorbable antibacterial envelope available for cardiac implantable electronic devices (CIEDs), including ICDs and pacemakers. The absorbable surgical mesh envelope contains two powerful antibiotics — minocycline and rifampin. It is designed to stabilise the device and help reduce the risk of infection and infection-related costs.1-5

Infections occur in about 1% to 4% of all CIED implantations,* resulting in a 50% patient mortality rate at 3 years6 and an average treatment cost to treat an infection of  of €36,722.6-10 The TYRX Envelope has been shown to reduce infection risks by 70% to 100% in high-risk patients.12- 16


The TYRX Envelope is intended to hold a pacemaker pulse generator or defibrillator securely in place in order to provide a stable environment when implanted in the body. The powerful antimicrobial agents, minocycline and rifampin, have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of the pacemaker or defibrillator.1-5 This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.


The TYRX Envelope is fully absorbable technology uniquely designed for Perfect-PocketTM Protection.

Proven stabilisation in holding CIEDs, such as pacemakers and ICDs, securely in place to provide a stable environment when implanted in the body.17-21

  • Reduces the chance of device migration, erosion, or Twiddler Syndrome.17-18

Synergistic combination of minocycline and rifampin shown to reduce infection associated with other medical devices in multiple, randomised controlled trials.1-5

  • Minocycline and rifampin elute locally into the tissue pocket enabling minimum inhibitory concentration (MIC) of the antibiotic drug levels in the tissue to be reached within 2 hours of implantation, which are maintained for a minimum of 7 days: locally eluted, adjunctive antibacterial protection.17-22
  • Non-systemic dose: TYRX Envelopes contain <5% of the recommended oral daily doses, 7.6 mg of minocycline & 11.9 mg of rifampin.22

The only antibacterial device available for CIED implants that is fully absorbable.

  • Fully absorbs into the body in approximately 9 weeks.17
  • Requires no adjustment to standard surgical techniques during replacement or revision procedure.
  • After absorption, no foreign body nidus for infection.

Novel , large-pore mesh knitted from bioabsorbable multifilaments coated with a bioabsorbable polyarylate polymer that breaks down into naturally occurring components. The composition of the mesh filament is similar to bioabsorbable suture.22


Bacterial infection is one of the most common causes of CIED complications, and it is on the rise.

Over a 15-year period, increase in incidence of infection was more than double the increase in implants (210% vs 96%).7

Change in CIED implants and infections between 1993-2008


The TYRX Envelope is made of large-pore knit filaments similar to a 5.0 suture. It’s coated in an amino acid tyrosine-based polymer, which disperses the antibiotics and breaks down over time, primarily via hydrolysis. The envelope is fully absorbed into the body in approximately 9 weeks.

TYRX Medium Envelope is 2.5” (6.3 cm) x 2.7” (6.9 cm), and the TYRX Large Envelope is 3.0” (7.6 cm) x 3.35” (8.5 cm).

The TYRX Envelope after implantation elutes antibiotics.

The TYRX envelope after implantation elutes antibiotics.

Four weeks post-op, the TYRX Envelope dissolves into fragments.

This is an image of the TYRX envelope four weeks post-op.

Nine weeks post-op, the TYRX Envelope fully absorbs.

This is an image of the Evera VR implantable cardioverter defibrillator.

Manufacturing the TYRX Absorbable Antibacterial Envelope - (03:51)

See the facility and meet the team behind TYRX.
More information (see more) Less information (see less)


Each TYRX Envelope contains a combination of minocycline and rifampin.

Minocycline is a bacteriostatic antimicrobial that inhibits protein synthesis and has been shown effective against gram-positive bacteria such as S aureus and gram-negative bacteria such as E coli, E aerogenes, H influenza, and A baumannii.*

The minocycline dose per TYRX Envelope is 5.1 mg (medium) and 7.6 mg (large).

Rifampin is a bactericidal antimicrobial that interferes with DNA-dependent RNA polymerase activity.23 It has been shown to be effective against gram-positive bacteria such as S aureus (including MRSA) and S epidermidis and gram-negative bacteria such as H influenza.

The rifampin dose per TYRX Envelope is 8.0 mg (medium) and 11.9 mg (large).


Find the Instructions for Use in the product labeling supplied with each device.


Infection rate is an aggregation of data; see data on file at Medtronic.

Medtronic Infection Control technology — based on inventions by Joachim Kohn, PhD, surrounding unique biodegradable polymer technology (i.e., tyrosine-derived polyarylates) — has received a world-wide license from Rutgers, The State University of New Jersey, which covers a broad range of absorbable materials and drug delivery technology. 


Hanna H et al. J Clin Oncol. 2004;22(15):3163-3171.


Leon C et al. Intensive Care Med. 2004;30(10):1891-1899.


Zambramski JM et al. J Neurosurg. 2003;98(4):725-730.


Chatzinikolaou I et al. Am J Med. 2003;115(5):352-357.


Raad I et al. Ann Intern Med. 1997;128(4):267-274.


Sohail MR et al. PACE. 2015;38(2):231-239.


Greenspon A et al. J Am Coll Cardiol. 2011;58(10):1001-1006.


Ahsan SY et al. Europace 2014;16(10):1482-1489


2014-15 Medicare 100% Standard Analytic File (SAF), data on file with Medtronic plc.


CPI 2016 Detailed Report: CPI1612. Assessed March, 2018.


Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY13.


Bloom HL et al. Pacing Clin Electrophysiol. 2011;34(2):133-142.


Mittal S et al. Heart Rhythm. 2014;11(4):595-601.


Kolek MJ et al. J Cardio Electrophysiol. 2015;26(10):1111-1116.


Shariff N et al. J Cardio Electrophysiol. 2015;26(10):783-789.


Henrikson CA et al. JACC EP.2017;3(10):1158-1167.


Huntingdon Life Sciences Study TR-2011-054.


Hirsh J. EP Lab Digest, July 2012;12(7).


Klinge U et al. Influence of Polyglactin-Coating on Functional Morphological Parameters of Polypropylene-Mesh Modifications For Abdominal Wall Repair. Biomaterials. 1999;20:613-623.


Pillai CKS et al. Absorbable Polymeric Surgical Sutures: Chemistry, Production, Properties, Biocompatibility and Performance. J Biomater Appl. 2010;25:291-366.


Ferrando JM et al. Early Imaging of Integration Response to Polypropylene Mesh in Abdominal Wall by Environmental Scanning Electron Microscopy: Comparison of Two Placement Techniques and Correlation with Tensiometric Studies. World J Surg. 2001;25:291-366.


TYRX Absorbable Antibacterial Instructions for Use.


The Sanford Guide to Antimicrobial Therapy. Web Edition. 2015: Antimicrobial Therapy Inc.; Hyde Park, VT.

TYRX™ Cardiac Absorbable Antibacterial Envelope

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScanTM device, see the MRI SureScanTM technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu

The envelope is intended to hold the following CIED securely to create a stable environment when implanted in the body at the following locations: Implantable Pulse Generator (IPG), Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Devices (CRT-P and CRT-D); implant locations are pectoral, abdominal, or flank (lateral to the body midline and superior to the gluteal) regions.

The envelope contains the ancillary medicinal substance ansamycin, which has been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of the device.

The envelope is contraindicated for use in patients with allergy or history of allergy to tetracyclines, ansamycin, or absorbable sutures; in patients with systemic lupus erythematosus (SLE) because minocycline has been reported to aggravate this condition; in contaminated or infected wounds.


All Medtronic TYRX Infection Control Products are protected under one or more of these patents:

U.S. Nos. 8315700, 8591531.
European (FR)(IE)(DE)(GB)(ES)(IT)(BE)(NL) patent no. 1484080B1.
European (FR)(DE)(GB)(IE)(IT)(BE)(ES)(NL) patent no. EP1028774B1.
European (GB)(FR)(IE)(DE)(CH)(NL) patent no. 1908490B1.

Medtronic TYRX™ owns or licenses an additional 70 patent applications worldwide covering proprietary products targeting cardiovascular, cosmetic surgical applications and other pharmaceutical applications.